Clinical trials: Cystic Fibrosis Lung
Cystic Fibrosis
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
The purpose of this study is to evaluate the safety of long-term ivacaftor treatment in participants with cystic fibrosis (CF) from Studies 110 (NCT01614457), 111 (NCT01614470), and 113 (NCT01685801).
- Trial name
- KONTINUE (NCT01707290)
- Testing
- Ivacaftor
- Where
- 38 sites in United States, Belgium and 2 more
- Volunteers
- 125 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis, Cystic Fibrosis in Children
Program Of Exercises During The Hospitalization Of Children And Adolescents With Cystic Fibrosis
The objective of this study was to evaluate the effect of a physical exercise program on the functional capacity of children and adolescents with cystic fibrosis hospitalized at the Hospital de Clínicas of Porto Alegre (HCPA)…
- Conditions
- Cystic Fibrosis, Cystic Fibrosis in Children, Cystic Fibrosis Pulmonary Exacerbation, Cystic Fibrosis With Exacerbation
- Trial name
- NCT03273959
- Testing
- Exercise protocol
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Cystic Fibrosis
Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation
The purpose of this study is to demonstrate that Miglustat restores the function of the cystic fibrosis transmembrane conductance regulator (CFTR) in adult patients with cystic fibrosis homozygous for the F508del mutation.
- Trial name
- MIGLUSTAT-CF (NCT02325362)
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cystic Fibrosis
A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis
The Sponsor is developing KB407, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human Cystic Fibrosis Transmembrane Conductance Regulator…
- Trial name
- NCT05095246
- Testing
- KB407 (Nebulization)
- Where
- Australia
- Sponsor
- Krystal Biotech, Inc.
Depression, Anxiety
Preventing Depression and Anxiety: A Cystic Fibrosis-Specific Cognitive Behavioral Therapy Intervention
Individuals with Cystic Fibrosis (CF) are at high risk for depression and anxiety, with negative consequences for quality of life, ability to carry out daily CF treatments, and health.
- Trial name
- NCT03992027
- Testing
- CF-CBT: A Cognitive-Behavioral Skills-Based Program to Promote Emotional Well-Being for Adults wtih Cystic Fibrosis, Waitlist Control
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Dyspnea, Lung Diseases
Effects of Automated Oxygen Titration Alone or With High Flow Nasal Therapy on Dyspnea and Exercise Tolerance
The main purpose of this study is to evaluate the effects of automated oxygen administration (FreeO2 system) alone or with high-flow oxygen on dyspnea and exercise tolerance in people with desaturating chronic lung disease…
- Conditions
- Dyspnea, Lung Diseases, Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT05267418
- Testing
- Automated nasal O2 titration with FreeO2
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Laval University
Cystic Fibrosis
Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers
Inflammation clearly contributes to the progression of the cystic fibrosis (CF) lung disease, and administration of the anti-inflammatory agent high-dose ibuprofen retards the rate of decline of pulmonary function.
- Trial name
- NCT00531882
- Testing
- Pioglitazone, Simvastatin, Ibuprofen
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Cystic Fibrosis
Effects of SIMEOX on Airway Clearance in Cystic Fibrosis
This study will investigate the contribution of SIMEOX technology on the effectiveness of bronchial drainage. This is a crossover study to evaluate the contribution of SIMEOX on the effectiveness of bronchial drainage (verified…
- Trial name
- NCT04187924
- Testing
- Autogenic drainage, SIMEOX + Autogenic drainage
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Cystic Fibrosis,
Evaluation of Bronchial Inflammation in Allergic Bronchopulmonary Aspergillosis (ABPA)
Chronic bronchial inflammation is an important clinical feature in cystic fibrosis. Approximately 10% of patients with cystic fibrosis suffer from Allergic Bronchopulmonary Aspergillosis.
- Trial name
- ABPA (NCT00906568)
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Cystic Fibrosis
Study of the Prevalence of Active/Passive Smoking and Vaping Among Patients With Cystic Fibrosis
In the collective unconscious, a patient with cystic fibrosis does not smoke. This belief is so deeply rooted that there is virtually no French data on the prevalence of smoking among this vulnerable population.
- Trial name
- Taba-Muco (NCT07342920)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Quality of Lifte, Cystic Fibrosis (CF)
Characterisation of a Population of Adults Suffering From Cystic Fibrosis in a Belgian Reference Center
This research project aims to better understand the consequences of diabetes on the quality of life, respiratory function, and nutritional status of patients with cystic fibrosis followed at a Belgian reference center and to…
- Conditions
- Quality of Lifte, Cystic Fibrosis (CF), Diabetes
- Trial name
- NCT07442682
- Where
- Belgium
- Volunteers
- 162 people
- Sponsor
- Erasme University Hospital
Cystic Fibrosis
Non-Invasive Biomarkers in Cystic Fibrosis
Background Chronic airway inflammation is present in cystic fibrosis. Non-invasive inflammometry may be useful in disease management.
- Trial name
- NCT00413140
- Where
- 4 sites in Netherlands
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Cystic Fibrosis
Manual Chest Physiotherapy and Active Cycle of Breathing Techniques (ACBT) in Patients of Cystic Fibrosis
Cystic fibrosis is a genetic disease (autosomal recessive) which involves malfunction of the exocrine glands, leading to abnormal secretions in the body.
- Trial name
- NCT05026918
- Testing
- MCPT, ACBT
- Where
- Pakistan
- Volunteers
- 14 people
- Sponsor
- Riphah International University
Cystic Fibrosis
A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients
The purpose of this research study is to test the pharmacokinetics, safety, and tolerability of an intravenous infusion of a drug called Ganite (gallium nitrate) in patients with cystic fibrosis.
- Trial name
- NCT01093521
- Testing
- 100 mg/m2 dose, 200 mg/m2 dose
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Washington
Cystic Fibrosis
Modulation by Sex Hormones of Inflammation and Susceptibility to Pseudomonas Aeruginosa in Cystic Fibrosis Airways
The general objective is to elucidate the mechanisms whereby sex hormones may modulate the severity of respiratory disease. An important component of this proposal is a systematic and intensive approach to characterize how the…
- Trial name
- NCT00700050
- Testing
- Hypertonic saline
- Where
- Canada
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- The Hospital for Sick Children
Cystic Fibrosis
Inhaled Mannitol on Mucociliary Clearance in Moderate to Severe Cystic Fibrosis
This study will provide important mechanistic information regarding the effect of inhaled mannitol (Bronchitol) in people with cystic fibrosis (PwCF) with moderate to severe disease who are already using…
- Trial name
- NCT05740618
- Testing
- Mannitol Inhalant Product
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of North Carolina, Chapel Hill
Cystic Fibrosis
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
This study will evaluate the safety and pharmacokinetics (PK) of lumacaftor (LUM) and ivacaftor (IVA) in participants 1 to less than 2 years of age with cystic fibrosis (CF), homozygous for F508del (F/F).
- Trial name
- NCT03601637
- Testing
- LUM, IVA
- Where
- 27 sites in United States, Canada
- Volunteers
- 61 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
Epidemiology and Clinical Characteristics of Non-Tuberculous Mycobacteria Infections in Cystic Fibrosis Patients.
An increase in the prevalence of infections due to non-tuberculous mycobacteria (NTM) is observed in many countries and recent data suggest the circulation of dominant clones with a possibility of human-to-human contamination.
- Trial name
- CIMENT (NCT03312075)
- Testing
- Sputum and blood samples
- Where
- 14 sites in France
- Volunteers
- 848 people
- Sponsor
- University Hospital, Brest
Cystic Fibrosis
Impact of Global Care of the Pain at Chronic Painful Patients Affected by Cystic Fibrosis
The purpose of this study is to evaluate the impact of the global approach to the pain in cystic fibrosis patients with chronic or intermittent pain.
- Trial name
- MUCO-SOPHRO (NCT01915875)
- Testing
- sophrology sessions at home
- Where
- France
- Volunteers
- 13 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cystic Fibrosis
Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis
This study evaluates the effects of 12-week treatment with two doses of tiotropium bromide (2.5 mcg q.d. and 5 mcg q.d.) compared to placebo administered via the Respimat device on lung function in patients with Cystic Fibrosis.
- Trial name
- NCT00737100
- Testing
- Tiotropium bromide 5 mcg, tiotropium bromide-low dose-2.5mcg
- Where
- 107 sites in United States, Australia and 9 more
- Volunteers
- 510 people
- Sponsor
- Boehringer Ingelheim